Biomedical research at Oslo University Hospital

Publications (original articles or review articles) published in 2021 from OUS - Department of Cancer Genetics

22 publications found

Akimov Y, Aittokallio T (2021)
Re-defining synthetic lethality by phenotypic profiling for precision oncology
Cell Chem Biol, 28 (3), 246-256
DOI 10.1016/j.chembiol.2021.01.026, PubMed 33631125

Aure MR, Fleischer T, Bjørklund S, Ankill J, Castro-Mondragon JA, OSBREAC, Børresen-Dale AL, Tost J, Sahlberg KK, Mathelier A, Tekpli X, Kristensen VN (2021)
Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer
Genome Med, 13 (1), 72
DOI 10.1186/s13073-021-00880-4, PubMed 33926515

Ben-Elazar S, Aure MR, Jonsdottir K, Leivonen SK, Kristensen VN, Janssen EAM, Kleivi Sahlberg K, Lingjærde OC, Yakhini Z (2021)
miRNA normalization enables joint analysis of several datasets to increase sensitivity and to reveal novel miRNAs differentially expressed in breast cancer
PLoS Comput Biol, 17 (2), e1008608
DOI 10.1371/journal.pcbi.1008608, PubMed 33566819

Berg J, Ramberg C, Haugstvedt JOS, Bengtson MB, Gabrielsen AM, Brustugun OT, Halvorsen AR, Helland Å (2021)
Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers
Front Oncol, 11, 674731
DOI 10.3389/fonc.2021.674731, PubMed 34109123

Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, Wahlström C, Pooley KA, Parsons MT, Fortuno C, Wang Q, Bolla MK, Dennis J, Keeman R, Alonso MR, Álvarez N, Herraez B, Fernandez V, Núñez-Torres R, Osorio A, Valcich J, Li M, Törngren T, Harrington PA, Baynes C et al. (2021)
Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women
N Engl J Med, 384 (5), 428-439
DOI 10.1056/NEJMoa1913948, PubMed 33471991

Galili B, Tekpli X, Kristensen VN, Yakhini Z (2021)
Efficient gene expression signature for a breast cancer immuno-subtype
PLoS One, 16 (1), e0245215
DOI 10.1371/journal.pone.0245215, PubMed 33434192

Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å (2021)
NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
J Transl Med, 19 (1), 232
DOI 10.1186/s12967-021-02905-3, PubMed 34059094

Hamfjord J, Guren TK, Glimelius B, Sorbye H, Pfeiffer P, Dajani O, Lingjaerde OC, Tveit KM, Pallisgaard N, Spindler KG, Kure EH (2021)
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer
Int J Cancer
DOI 10.1002/ijc.33672, PubMed 33961700

Haugen MH, Lingjærde OC, Hedenfalk I, Garred Ø, Borgen E, Loman N, Hatschek T, Børresen-Dale AL, Naume B, Mills GB, Mælandsmo GM, Engebraaten O (2021)
Protein Signature Predicts Response to Neoadjuvant Treatment With Chemotherapy and Bevacizumab in HER2-Negative Breast Cancers
JCO Precis Oncol, 5
DOI 10.1200/PO.20.00086, PubMed 34036235

Herring S, Oda JM, Wagoner J, Kirchmeier D, O'Connor A, Nelson EA, Huang Q, Liang Y, DeWald LE, Johansen LM, Glass PJ, Olinger GG, Ianevski A, Aittokallio T, Paine MF, Fink SL, White JM, Polyak SJ (2021)
Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs
Antimicrob Agents Chemother, 65 (4)
DOI 10.1128/AAC.01146-20, PubMed 33468464

Ianevski A, Lahtela J, Javarappa KK, Sergeev P, Ghimire BR, Gautam P, Vähä-Koskela M, Turunen L, Linnavirta N, Kuusanmäki H, Kontro M, Porkka K, Heckman CA, Mattila P, Wennerberg K, Giri AK, Aittokallio T (2021)
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
Sci Adv, 7 (8)
DOI 10.1126/sciadv.abe4038, PubMed 33608276

Jaiswal A, Gautam P, Pietilä EA, Timonen S, Nordström N, Akimov Y, Sipari N, Tanoli Z, Fleischer T, Lehti K, Wennerberg K, Aittokallio T (2021)
Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor
Mol Syst Biol, 17 (3), e9526
DOI 10.15252/msb.20209526, PubMed 33750001

Janiszewska M, Stein S, Metzger Filho O, Eng J, Kingston NL, Harper NW, Rye IH, Alečković M, Trinh A, Murphy KC, Marangoni E, Cristea S, Oakes B, Winer EP, Krop IE, Russnes HG, Spellman PT, Bucher E, Hu Z, Chin K, Gray JW, Michor F, Polyak K (2021)
The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer
JCI Insight, 6 (11)
DOI 10.1172/jci.insight.147617, PubMed 33886505

Johannesen TB, Smeland S, Aaserud S, Buanes EA, Skog A, Ursin G, Helland Å (2021)
COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway
Front Oncol, 11, 652535
DOI 10.3389/fonc.2021.652535, PubMed 33842366

Johansson ALV, Trewin CB, Fredriksson I, Reinertsen KV, Russnes H, Ursin G (2021)
In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study
Breast Cancer Res, 23 (1), 17
DOI 10.1186/s13058-021-01393-z, PubMed 33526044

Krüger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, Garred Ø, Naume B, Engebraaten O, Akslen LA (2021)
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Sci Rep, 11 (1), 3388
DOI 10.1038/s41598-021-81914-0, PubMed 33564016

Lilleborge M, Falk RS, Sørlie T, Ursin G, Hofvind S (2021)
Can breast cancer be stopped? Modifiable risk factors of breast cancer among women with a prior benign or premalignant lesion
Int J Cancer
DOI 10.1002/ijc.33680, PubMed 33990967

Maagdenberg H, Oosterom N, Zanen J, Gemmati D, Windsor RE, Heil SG, Esperón P, Jabeen S, Ruiz-Argüelles GJ, Zolk O, Hoerning S, Sleurs C, Lopéz-Lopéz E, Moreno-Galván M, van den Heuvel-Eibrink MM, Maitland-van der Zee AH, Carleton BC (2021)
Genetic variants associated with methotrexate-induced mucositis in cancer treatment: A systematic review and meta-analysis
Crit Rev Oncol Hematol, 161, 103312
DOI 10.1016/j.critrevonc.2021.103312, PubMed 33794308

Park J, Choi JY, Choi J, Chung S, Song N, Park SK, Han W, Noh DY, Ahn SH, Lee JW, Kim MK, Jee SH, Wen W, Bolla MK, Wang Q, Dennis J, Michailidou K, Shah M, Conroy DM, Harrington PA, Mayes R, Czene K, Hall P, Teras LR, Patel AV et al. (2021)
Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?
Cancers (Basel), 13 (10)
DOI 10.3390/cancers13102370, PubMed 34069208

Siddiqui FA, Parkkola H, Vukic V, Oetken-Lindholm C, Jaiswal A, Kiriazis A, Pavic K, Aittokallio T, Salminen TA, Abankwa D (2021)
Novel Small Molecule Hsp90/Cdc37 Interface Inhibitors Indirectly Target K-Ras-Signaling
Cancers (Basel), 13 (4)
DOI 10.3390/cancers13040927, PubMed 33672199

Tanoli Z, Vähä-Koskela M, Aittokallio T (2021)
Artificial intelligence, machine learning, and drug repurposing in cancer
Expert Opin Drug Discov
DOI 10.1080/17460441.2021.1883585, PubMed 33543671

Terkelsen T, Pernemalm M, Gromov P, Børresen-Dale AL, Krogh A, Haakensen VD, Lethiö J, Papaleo E, Gromova I (2021)
High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers
Mol Oncol, 15 (2), 429-461
DOI 10.1002/1878-0261.12850, PubMed 33176066